Explore

Recent news and media from the Citizen Stash squad.

Citizen Stash Cannabis Corp. now trading under symbol “CSC” on the TSX.V

Vancouver, British Columbia, June 17 2021, Citizen Stash Cannabis Corp. (Formerly Experion Holdings Ltd.) (the “Company“ or “Citizen Stash”) (TSXV:CSC) (OTCQB:EXPFF) (FRANKFURT:MB31) is pleased to announce that the Company is now trading under the symbol “CSC” on the TSX.V.  

The Company wishes to remind investors and the market that Citizen Stash (formally Experion Holding Ltd.) is now trading under its new symbol “CSC” on the TSX Venture Exchange.  

The Company’s board of directors approved the implementation of the name change following approval from the shareholders at the annual general and special virtual-only meeting of shareholders held on May 26, 2021. On June 15, 2021, the common shares of the Company commence trading on the TSX Venture Exchange under its new name, “Citizen Stash Cannabis Corp.” and under its new trading symbol “CSC.V”. 

No action is required to be taken by current shareholders in connection with the name change. As a result of the name change, the Company’s common share CUSIP number is changed to 17291F108 and the ISIN is changed to CA17291F1080.  

The Company will also be changing its trading symbol on the OTCQB and will inform the market once transitioned.  

 

About Citizen Stash Cannabis Corp. 

Citizen Stash is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC.  

Citizen Stash is best known as a rapidly growing adult-se premium cannabis brand offered nationally in 7 provinces and territories.  Citizen Stash invested and developed a portfolio of premium cannabis genetics, strains and products with a unique growth strategy incorporating a highly scalable aggregation and distribution business model to drive revenues across its national sales network.  

Citizen Stash trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “CSC” on the OTCQB Venture under the symbol “EXPFF” and on the Frankfurt Stock Exchange under the symbol “MB31”. 

 

For further information, please visit the Company’s website www.experionwellness.com or contact Investor Relations, Email: IR@experionwellness.com. 

 

Disclosure 

This news release contains “forward-looking statements” and “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of material factors, assumptions, risks and uncertainties, many of which are beyond the control of the Company. 

Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “continues”, “future”, “forecasts”, “potential”, “outlook” and similar expressions, or are events or conditions that “will”, “would”, “may”, “likely”, “could”, “should”, “can”, “typically”, “traditionally” or “tends to” occur or be achieved. This news release contains forward-looking statements, pertaining to, among other things, the following: The Company’s capital spending forecast and expectations of how it will be funded; near-term impacts from the COVID-19 pandemic; the Company’s capital management strategy and financial position; the impact of governmental and Company measures implemented in response to the COVID-19 pandemic; the Company’s outlook, activity levels, supply chains and sales channels; loss of markets; further legislative and regulatory developments involving cannabis or otherwise affecting the Company’s business or its consumers generally, including delays in the issuance of licenses; competition; currency and interest rate fluctuations; and marketing costs. 

Although the Company believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements are made, undue reliance should not be placed on the forward-looking statements because the Company can give no assurances that such statements and information will prove to be correct and such statements are not guarantees of future performance. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. 

Actual performance and results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to: known and unknown risks, including those set forth in the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis (“MD&A”) (a copy of which can be found under Experion’s profile on SEDAR at www.sedar.com); a significant expansion of COVID-19 pandemic and the impacts thereof; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategy; integration of acquisitions, competition, and uncertainties resulting from potential delays or changes in plans with respect to acquisitions, development projects or capital expenditures and changes in legislation; stock market volatility and the inability to access sufficient capital from external and internal sources; general economic, market or business conditions including those in the event of an epidemic, natural disaster or other event; global economic events; changes to the Company’s financial position and cash flow; the availability of qualified personnel, management or other key inputs; currency exchange fluctuations; changes in political and security stability; potential industry developments; and other unforeseen conditions which could impact the Company. Accordingly, readers should not place undue importance or reliance on the forward-looking statements. Readers are cautioned that the foregoing list of factors is not exhaustive and should refer to “Risk Factors” set out in the MD&A. 

Statements, including forward-looking statements, contained in this news release are made as of the date they are given and the Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

SOURCE: Citizen Stash Cannabis Corp. 

 

, , , , ,

Viridium Reports Year End Results, Provides Corporate Update

March 18, 2019: Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to provide shareholders with the year end financials and a corporate update.

Year End

Viridium has now filed the year end consolidated financial statements and management discussion and analysis for the year ending November 30, 2018 on SEDAR.

Company Updates

Viridium and its wholly owned subsidiary, Experion Biotecnologies (“Experion”), a licensed cultivation and processor company under the Cannabis Act, have progressed on many fronts over the last six months. After receiving its transitional license from the ACMPR to the Cannabis Act last October, the Company focused on sales, product and brand development. On the wholesale front, Experion has supplied both cannabis flower and starting materials to over 7 licensed cultivators throughout Canada generating over $1 Million in sales since September 2018. These relationships continue to foster into strategic partnerships and potential supply agreements.

In early December 2018 and January 2019, Experion launched its first adult use cannabis brand, Citizen Stash, during the O’Cannabis Expo and Lift & Co Conference in Vancouver. Citizen Stash cannabis products are hand cultivated in Experion’s indoor facility to high standards to ensure exceptional user experience.  Experion signed a supply agreement with the BC Liquor Distribution branch to supply the province of British Columbia, followed with its first shipment shortly after. Our Citizen Stash products can now be found online and at stores.  Experion also signed an agreement with Open Fields Distribution in February to supply the province of Saskatchewan, with a shipment scheduled in the next couple of weeks. The first retail strain under Citizen Stash offered for both provinces is the Lemon Zkittle, a 60% sativa hybrid with mid to high THC, offering the user a relaxing and consistent quality effect.

Internationally, Viridium has also entered the tender process in December 2018, with the opportunity to become one of the first licensed medical cannabis companies in Germany with partner INOPHA Pharma. An indoor GMP facility capable of producing 3,000 KG per year designed by the Viridium team, including all the support processes and procedures, was submitted as part of the tender documents. Should the tender application become successful, Viridium would continue to support the implementation and construction of the facility and become an equity partner in the licensed joint venture. Regardless if the tender is successful or not, INOPHA and Viridium will continue with an import and export relationship for medical cannabis throughout Germany.

Corporately, Viridium completed the Amalgamation of EFX Laboratories in February 2019. The Amalgamation is consistent with Viridium’s stated goal of producing a strong portfolio of cannabis brands and products for the Canadian medical, wellness, and export markets and the financial and strategic benefits of the Amalgamation are uniquely compelling to shareholders of both Viridium and EFX. The Amalgamation provides a strong go-forward strategy that creates a long-term sustainable growth company focused on the “3rd wave” of investment which includes cannabis biotech applications in the retail consumer product market.

The Amalgamation enables the acceleration of completing Viridium’s and EFX’s business initiatives in the next 24 to 36 months given the strong combined balance sheet with more than $10 million cash on hand and debt free. Viridium, as combined with EFX, is now vertically integrated from seed to value added product, and has all of the Health Canada Licences it requires to execute its business strategy.

Recently, Viridium graduated from Tier 2 to Tier 1 on the TSX Venture Exchange on February 25, 2019.

About Viridium 

Viridium Pacific Group Ltd. is the parent company of Experion Biotechologies Inc., a Health Canada licensed cultivation and processor of cannabis, based in Mission, BC and EFX labs, a medical products production and clinical research company based out of Calgary, AB.

Viridium is invested in a portfolio of products including a full spectrum of consumer needs, including products for Adult use, wellness and therapeutic daily use.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific Group Ltd.
Jarrett Malnarich
Tel: (604) 837-8688
info@viridiumpacific.com

 

Disclosure      

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

, , , , , , , , , , , , , , , ,

Viridium Announces Graduation from Tier 2 to Tier 1 of the TSX Venture Exchange

February 25, 2019 Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to announce it has met the requirements of Tier 1 on the TSX Venture Exchange effective February 25, 2019. Tier 1 is reserved for the most advanced issuers with the most significant financial resources on the TSX Venture Exchange.

Jay Garnett, Viridium’s President and Chief Executive Officer commented: “Viridium’s graduation to Tier 1 of the TSX Venture Exchange is a further demonstration of the quality of our company’s strength with the recent merging with EFX and of our management team. Graduating to Tier 1 status will provide the Company with a more favorable regulatory environment, decreased filing requirements and increased opportunity for participation by institutional investors. We would like to thank the TSX Venture Exchange for recognizing Viridium’s rapid growth over the past couple of years, which was demonstrated by Viridium’s license with Health Canada to grow and sell its medical cannabis.”


About Viridium

 Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.), medical product production (EFX Labs), property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.). Experion Biotechnologies Inc., is a Health Canada licensed cultivator and processor of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.


For further information:
www.viridiumpacific.com
Jarrett Malnarick,
Info@viridiumpacific.com
604 837 8688

Disclosure      

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

 

, , , , , , , , , , , , ,

Stand for Something

Subscribe to our newsletter for updates
and curated content delivered to: